A pro bono partnership using AI to make blood sample collection easier for patients
Castor is proud to announce a pro bono collaboration with the Leukemia & Lymphoma Society (LLS) on a groundbreaking study designed to improve the way blood samples are collected and monitored for patients with blood disorders. The initiative aims to validate a more accessible, less invasive method for Complete Blood Count (CBC) testing using the Tasso at-home blood collection device.
By leveraging Castor’s AI-powered clinical trial platform, the LLS study team was able to rapidly build and deploy the study protocol—accelerating study launch timelines while maintaining quality and compliance through human-supervised QA processes.
“At Castor, we believe AI should do more than automate—it should empower,” said Derk Arts, CEO of Castor Research Inc.
“This collaboration with LLS demonstrates how technology can improve the research process while putting patients first.”
The study evaluates the performance of the Tasso device versus traditional venipuncture to determine whether a patient-friendly, remote sampling option can be adopted for ongoing monitoring of blood cancers such as leukemia and lymphoma. The goal is to reduce patient burden and make routine testing easier—especially for those who face geographic, physical, or psychological barriers to accessing care.
LLS, the world’s largest voluntary health organization dedicated to fighting blood cancers, views this partnership as a significant step forward in modernizing patient care.
Ashley Yocum, PhD Executive Research Strategy Lead, Beat AML Master Trial, Leukemia & Lymphoma Society said:
“We are excited to work with Castor and leverage their platform to explore less invasive options for patients living with blood disorders…
This partnership helps advance our mission to deliver better care and more compassionate solutions for those who need them most.”
This partnership reflects Castor’s long-standing commitment to accelerating clinical research through technology—while ensuring that innovation serves both science and society.
This partnership is one of many ways Castor is working to make smarter, more compassionate research possible for all. Whether it’s enabling patient-friendly innovation through AI or helping underfunded researchers stay afloat, our mission remains the same: to accelerate research that improves lives.
👉 Read how we’re helping preserve critical research in the face of NIH funding cuts through Castor Essentials: Castor Steps Up to Preserve Critical Research
About Castor Research Inc.
Castor is a leading provider of AI-powered clinical trial technology that accelerates study design, streamlines data capture, and enhances patient engagement. From remote trials to real-world evidence and device studies, Castor’s platform enables sponsors and researchers to launch studies faster, collect higher-quality data, and reduce operational burden. Headquartered in the U.S. and the Netherlands, Castor supports leading academic institutions, emerging biotechs, and global pharmaceutical companies in conducting smarter, more accessible research.
About the Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to funding blood cancer research, education, and patient services. LLS’s mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma, and improve the quality of life of patients and their families.
Media Contact:
Kevin Thornton, Director of Marketing, Castor
[email protected] | 919-579-8690
